Department of Human Papillomavirus and оthers оncovirus Research

Diagnosis and treatment of cervical cancer (CC) is an important problem of women's reproductive health. More than 500,000 new cases of the disease are diagnosed in the world every year, of which over 50% are fatal. The human papillomavirus (HPV) in 1996 was officially recognized by WHO as an etiological factor in the development of cervical cancer. Knowledge of the mechanisms of cervical cancer development, from the moment of infection with HPV to the development of cervical cancer, takes an average of 5-10 years, which makes this oncological disease by far the most "controllable" and preventable. The costs of organizing, screening cervical cancer, treatment of precancerous conditions (cryotherapy, electrocoagulation or conization of the cervix) are many times less than the costs of treating advanced forms of invasive cervical cancer (volumetric surgeries, radiation and chemotherapy, long-term rehabilitation).

The success of cervical cancer screening depends on the following factors: the degree of knowledge of the epidemiology of the disease; from the presence of a single comprehensive screening program approved by the Ministry of Health; on the level of awareness of the population and the skills of personnel in the technique of taking, fixing a smear and filling out an accompanying document; from using the database to conduct analysis and determine the direction of further work. Of all the above factors, the main ones at the moment are informing the population and training the medical staff in the technique of material collection. The test characteristics depend on the quality of the cytological smear.

In this regard, the Research Institute of Virology is studying the effectiveness of using at the population level the primary methods of screening for cervical cancer - liquid cytology (Pap test) and HPV DNA testing, with further genotyping, of the Human Papilloma Virus (HPV). A research project jointly with KOFIH "Improvement of research and diagnosis of human papillomavirus (HPV) in the Republic of Uzbekistan" will contribute to the development of evidence-based recommendations for the use of the above primary screening methods to identify precancerous conditions and further strengthen the health of women in our Republic, as well as contribute to capacity building medical institutions in Uzbekistan.

Abdukadyrova Muazzam Alievna

Head of department of papillomavirus and other oncoviruses research

1969-1974. - Student at Tashkent State Medical Institute

1974-1976 - Doctor of internship at the medical sanitary unit of the Tashkent Main Construction Department

1976-1980 - Postgraduate student at the Tashkent Institute of Cybernetics

1980-1989 - Junior researcher at the scientific research institute of virology

1989-1993. - Senior fellow at Scientific-Research Institute of Virology

1993-2003 - Head of the Clinical Laboratory of the Scientific Research Institute of Virology

2003-2021 - Head of the scientific grant of the Scientific Research Institute of Virology

2021 - present - Head of the Department of Research of papillomavirus and other oncoviruses of the virus and other oncoviruses